Apple wins bid to pause Apple Watch ban at US appeals court
Apple’s temporary win in pausing a U.S. import ban on certain Apple Watch models over alleged patent infringement has reignited debate over how the patent system treats big tech versus smaller innovators. Commenters examine whether Apple should license Masimo’s blood-oxygen sensing technology, redesign its hardware, or acquire the company, while noting that the ban stems from an ITC ruling rather than a full court judgment on patent validity. The conversation broadens into questions about whether patent enforcement promotes or hinders innovation, the ethics of “stealing” versus licensing IP, and how appeals and injunctions can advantage deep-pocketed firms.
Scope of the ban and the temporary pause
- The ban arises from an ITC finding of patent infringement, not from safety concerns.
- Many see pausing the import ban during the early appeal phase as reasonable: the case isn’t fully settled, and harms that can be fixed with money should not outweigh potentially irreversible business damage or reputational harm.
- Others argue injunctions are meant to be prospective; letting sales continue through long appeals shifts power toward rich defendants and undermines the remedy.
- The stay is short and procedural for now (tied to briefing deadlines), with a bond effectively set to zero, so there’s no financial penalty during this window.
Validity and nature of the patents
- Some insist patents are presumed valid once granted and note that the ITC would have implicitly treated them as such.
- Others stress that no court has yet ruled on validity, and that this ITC pathway is faster and can be abused by weak-patent holders.
- One technical description says the core patents relate to specific LED/photodiode arrangements and signal processing for blood oxygen sensing in a watch; some view these as legitimate and quite specific, others as “obvious” or weak.
Ethics of infringement vs. “stealing”
- Several comments push back on labeling patent infringement as “stealing,” distinguishing it from espionage or physical theft.
- Others respond that copying a patented method is morally akin to theft, and that refusing to license or pay royalties reflects a pattern by large tech firms.
- A broader debate unfolds about whether the greater good of widespread access to health tech outweighs strict enforcement of patents.
Apple’s and Masimo’s strategies and incentives
- Apple is seen as trying to stall: appeal, seek a customs-approved redesign (possibly software-only), and then ship a hardware revision that avoids the patents.
- Some believe damages, even with treble provisions, may ultimately be cheaper than an acquisition or a rich license.
- Masimo is portrayed by some as an aggressive but legitimate medical-device company, by others as acting like a de facto patent troll using the ITC to gain leverage or protect high-margin, insurer-focused products.